Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite stable colorectal cancer and no active liver metastases
Jul 4, 2025
Schlechter, et al.
Filter by
AGEN2373 (CD137 Agonist), INCAGN1876 (GITR Agonist), INCAGN1949 (OX40 Agonist)
Human Antibodies
Jan 1, 2017
Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities
Waight, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) GI
Jun 29
- Jul 2, 2022
Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer.
Bullock, et al.
Balstilimab (PD-1 Antagonist), Zalifrelimab (CTLA-4 Antagonist)
Journal of Clinical Oncology
Dec 21, 2021
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.
O’Malley, et al.
Balstilimab (PD-1 Antagonist), Zalifrelimab (CTLA-4 Antagonist)
Future Oncology
Aug 19, 2021
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.
O’Malley, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Clinical Cancer Research
Jul 1, 2022
Facts and Hopes in Immunotherapy of Pancreatic Cancer
Bockorny B, et al.
Frontiers in Immunology
Aug 7, 2019
Mutation-Derived Neoantigens for Cancer Immunotherapy.
Castle, et al.
Zalifrelimab (CTLA-4 Antagonist)
American Association for Cancer Research (AACR)
Apr 16
- Apr 20, 2016
AGEN1884 and AGEN2041: Two Functionally Distinct anti-CTLA-4 Antagonist Antibodies.
Drouin, et al.
Zalifrelimab (CTLA-4 Antagonist)
American Association for Cancer Research (AACR)
Apr 1
- Apr 5, 2017
AGEN1884, an IgG1 anti-CTLA-4 Antibody, Combines Effectively with PD-1 Blockade in Primary Human T Cell Assays and in a Non-human Primate Pharmacodynamic (PD) Model.
Drouin, et al.
Zalifrelimab (CTLA-4 Antagonist)
American Society of Clinical Oncology (ASCO)
Jun 2
- Jun 6, 2017
Phase 1, Open-Label, Multiple-Ascending-Dose Trial of AGEN1884, an Anti–CTLA-4 Monoclonal Antibody, in Advanced Solid Malignancies.
Wilky, et al.
Zalifrelimab (CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 12, 2017
Characterization of the anti-CTLA-4 Antibody AGEN1884, Including Toxicology and Pharmacology Assessments in Non-human Primates.
Gombos, et al.
Zalifrelimab (CTLA-4 Antagonist)
American Association for Cancer Research (AACR)
Apr 14
- Apr 18, 2018
Evaluation of Peripheral T Cell Subset Proliferation as a Pharmacodynamic Assay to Guide the Development of Anti-CTLA-4 and PD-1 Antibody Combinations in Patients With Solid Tumors.
de Souza, et al.
Zalifrelimab (CTLA-4 Antagonist)
American Society of Clinical Oncology (ASCO)
Jun 1
- Jun 5, 2018
Phase One Open-Label, Ascending Dose Trial of AGEN1884, an Anti-CTLA-4 Monoclonal Antibody, in Advanced Solid Malignancies: Dose Selection for Combination with PD-1 Blockade.
Wilky, et al.